{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:00:10Z","timestamp":1790456410398,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010564","name":"German Center for Lung Research","doi-asserted-by":"publisher","award":["FKZ 82DZLJ73B2"],"award-info":[{"award-number":["FKZ 82DZLJ73B2"]}],"id":[{"id":"10.13039\/501100010564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jcf.2026.07.1984","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:36:51Z","timestamp":1785382611000},"page":"859-866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world population pharmacokinetic modeling of elexacaftor, tezacaftor, and ivacaftor"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9849-9901","authenticated-orcid":false,"given":"AK","family":"Kunzelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Naehrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Shad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Breuling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4083-8146","authenticated-orcid":false,"given":"M","family":"Goetschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5110-346X","authenticated-orcid":false,"given":"K","family":"Habler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Sommerburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LM","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9076-3943","authenticated-orcid":false,"given":"J","family":"Starp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2745-2475","authenticated-orcid":false,"given":"M","family":"Vogeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Paal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4375-0923","authenticated-orcid":false,"given":"U","family":"Liebchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2026.07.1984_bib0001","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0002","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.biochem.75.103004.142532","article-title":"CFTR function and prospects for therapy","volume":"77","author":"Riordan","year":"2008","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0003","series-title":"Kaftrio-H-C-005269-WS-2551: assessment report - Variation","year":"2025"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0004","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s40262-025-01516-1","article-title":"Population pharmacokinetics of Elexacaftor, Tezacaftor and Ivacaftor in a real-world cohort of adults with cystic fibrosis","volume":"64","author":"Magnas","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0005","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0006","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor\/tezacaftor\/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0007","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3390\/pharmaceutics14081674","article-title":"Therapeutic drug monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in cystic fibrosis: where are we now?","volume":"14","author":"Choong","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0008","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/jpm11060458","article-title":"CFTR modulators: does one dose fit all?","volume":"11","author":"Van Der Meer","year":"2021","journal-title":"JPM"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0010","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jcf.2024.03.010","article-title":"Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor","volume":"23","author":"Vonk","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0011","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1111\/bcp.14844","article-title":"Accuracy of documented administration times for intravenous antimicrobial drugs and impact on dosing decisions","volume":"87","author":"Roydhouse","year":"2021","journal-title":"Brit J Clin Pharma"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0012","series-title":"Population pharmacokinetics: guidance for industry","year":"2022"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0013","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/jpm14101065","article-title":"Therapeutic drug monitoring of Elexacaftor, Tezacaftor, and Ivacaftor in adult people with cystic fibrosis","volume":"14","author":"Naehrig","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0014","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1515\/cclm-2021-0724","article-title":"Isotope dilution LC-MS\/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum","volume":"60","author":"Habler","year":"2022","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2013a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0016","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","article-title":"Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM","volume":"101","author":"Keizer","year":"2011","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0017","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40262-023-01342-3","article-title":"Lumacaftor\/Ivacaftor population pharmacokinetics in pediatric patients with cystic fibrosis: a first step toward personalized therapy","volume":"63","author":"Bouazza","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0018","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40262-025-01507-2","article-title":"Pharmacokinetics of ivacaftor, Tezacaftor, Elexacaftor, and lumacaftor in special cystic fibrosis populations: a systematic review","volume":"64","author":"Elzinga","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0019","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70245","article-title":"Elexacaftor\/Tezacaftor\/Ivacaftor population pharmacokinetics in pediatric patients with cystic fibrosis","volume":"18","author":"Truong","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0021","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s41030-020-00124-7","article-title":"Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"6","author":"Tsai","year":"2020","journal-title":"Pulm Ther"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0022","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.577263","article-title":"Insights into patient variability during ivacaftor-lumacaftor therapy in cystic fibrosis","volume":"12","author":"Hanafin","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0023","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1067\/mcp.2002.121829","article-title":"Changes in plasma protein binding have little clinical relevance","volume":"71","author":"Benet","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0024","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.freeradbiomed.2021.11.012","article-title":"Metabolism of natural forms of vitamin E and biological actions of vitamin E metabolites","volume":"179","author":"Jiang","year":"2022","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0025","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/nu14071341","article-title":"Pancreatic enzyme replacement therapy in cystic fibrosis","volume":"14","author":"Freswick","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/medicines12010001","article-title":"The pharmacokinetic changes in cystic fibrosis patients population: narrative review","volume":"12","author":"Awaness","year":"2025","journal-title":"Medicines"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0027","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myae020","article-title":"Evaluation of the drug\u2013drug interaction between triazole antifungals and cystic fibrosis transmembrane conductance regulator modulators in a real-life cohort","volume":"62","author":"Jansen","year":"2024","journal-title":"Med Mycol"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0028","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jcf.2024.01.006","article-title":"Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor\/ivacaftor","volume":"23","author":"Smeets","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2026.07.1984_bib0029","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/psp4.12611","article-title":"Approaches to handling missing or \u201cproblematic\u201d pharmacology data: pharmacokinetics","volume":"10","author":"Irby","year":"2021","journal-title":"CPT Pharmacom Syst Pharma"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326036593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199326036593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:27:26Z","timestamp":1790454446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199326036593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1569199326036593"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2026.07.1984","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world population pharmacokinetic modeling of elexacaftor, tezacaftor, and ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2026.07.1984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}